medigraphic.com
ISSN 1561-302X (Print)

2021, Number 3

<< Back Next >>

Rev cubana med 2021; 60 (3)

Evaluation of hepatic fibrogenesis in patients with nonalcoholic steatohepatitis treated with cuban oral red propolis

Velbes MPE, Martínez BS, Soto MJ, Hernández CJL, Pérez PA

Language: Spanish
References: 17
Page: 1-12
PDF size: 297.04 Kb.


ABSTRACT

Introduction: Nonalcoholic fat deposition disease is a pandemic in the contemporary world. Its silent spectrum goes through stages of chronicity and it can reach liver cirrhosis and on this a hepatic carcinoma could develop. There are no treatments and medical handling can act on only risk factors.
Objective: To evaluate cytohepatoprotective and antifibrotic effect of oral Cuban red propolis in patients with nonalcoholic steatohepatitis.
Methods: A prospective longitudinal study was carried out in selected patients from the Gastroenterology, Endocrinology and Internal Medicine consultations at Hermanos Ameijeiras Clinical Surgical Hospital from April 2017 to April 2018. The study universe was 120 patients with imaging diagnosis of fatty liver. The sample consisted of 70 patients with fatty liver diagnosis, who met the inclusion and exclusion criteria. Frequency and percentage analysis for the demographic variables were the statistical tests applied. The T test for the related samples evaluated the enzymatic behavior at the beginning and at the end of the treatment and the elastography changes were analyzed using Kappa and percentage tests.
Results: The biochemical variables studied showed statistically significant decrease at the end of the treatment, which evidenced the effectiveness of the treatment. 91.4% of the patients progressed to a lower degree of fibrosis.
Conclusions: Cuban red propolis proved to be a therapeutic drug with cytohepathoprotective and antifibrotic action.


REFERENCES

  1. Domínguez M, González Casas J, Jiménez M. Etiopatogenia, diagnóstico y tratamiento de la enfermedad del hígado graso no alcohólico. Rev. Esp. Enferm. Diag. 2013[acceso: 01/03/2020];105(7):409-20. Disponible en: Disponible en: https://scielo.isciii.es/pdf/diges/v105n7/es_punto_vista.pdf

  2. Verdelho Machado M, Cortés Pinto H. Non-alcoholic fatty liver disease: What the clinician needs to know. World J Gastroenterol. 2014;20(36):12956-80. Disponible en: https://doi.org/10.3748/wjg.v20.i36.12956

  3. Díaz Morales MR, Alonso Rodríguez C, Velbes Marquetti P, Hidalgo Cast T. Sobre las asociaciones entre el hígado graso no alcohólico y la insulino resistencia. Revista Cubana de Alimentación y Nutrición. 2017[acceso: 02/06/2020];27(1):1561-2929. Disponible en: Disponible en: http://www.revalnutricion.sld.cu/index.php/rcan/article/viewFile/253/pdf_21

  4. Chao Pereira C. Obesidad y mortalidad en los pacientes con insuficiencia cardiaca crónica. Revista Cubana de Medicina. 2018[acceso: 15/06/2020];57(4). Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_issuetoc&pid=0034-752320180004&lng=es&nrm=iso

  5. International Diabetes Federation: IDF. Diabetes Atlas: Key Messages. 2008[acceso: 01/02/2019]. Disponible en: Disponible en: http://diabetesatlas.org/key-messages.html

  6. Golabi, P., Paik, J., Reddy, R. et al. Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States. BMC Gastroenterol. 2019;19:56. https://doi.org/10.1186/s12876-019-0972-6

  7. Gil D, Kagana Valdés G, Cuesta O, Cuellar A, Vázquez A, Ferras BI, et al. Actividad inhibitoria del propóleos rojo cubano de Nueva Paz y Melena del Sur. IV Simposio de Propóleos y 111 de Apiterapia. La Habana. Cuba. 1996B.

  8. García Rochet C, Balbuena E, Domínguez E. Esteatosis hepática en diabéticos comportamiento en el Hospital saturnino Lora durante un año. Instituto Superior de Ciencias Médicas Santiago de Cuba; 2005. N. del T: En español (Tesis).

  9. Pérez Acosta GM, Velbes Marquetti P, Domínguez Álvarez C. Factores pronósticos de la fibrosis hepática en pacientes diabéticos, tipo 2 con hígado graso no alcohólico. Hermanos Ameijeiras. C. Habana; 2009. En español (Tesis).

  10. Osman MM, Osman KA, Ahmed MH. Abnormal glucose tolerance and non-esterified fatty acids (NEF As) as predictors of non-alcoholic steatohepatitis (NASH): which Ash that ignites the NASH. J Clin. Gastroenterol. 2007;41(1):118-9.

  11. Prof. D. Kersenovich (Conferencias). Fibrogénesis hepática. Stress oxidativo (comunicación personal/2015) Departamento de Medicina Experimental. Universidad Autónoma de México (UNAM 2015).

  12. Fernández Vega D, Velbes Marquetti PE, Nassip Hadah A, Domínguez Alvarez C, Soto Matos J, Giralt Rivero T. Efecto del tratamiento con extracto de propóleos rojo oral en la Esteatohepatitis no alcohólica. Rev. Cub. de Medicina. 2014;53(3):282-90.

  13. Pietrangelo A. Metals Oxidative stress and hepatic fibrogénesis. Semin Liver Dis. 1998;16:13-30.

  14. Rafeeg A, Kenneth C. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Annals of Medicine. 2009[acceso: 21/06/2020]:1-14. Disponible en: Disponible en: https://www.tandfonline.com/doi/full/10.1080/07853890802552437

  15. Petta S. Monitoring occurrence of liver-related events and survival by transient elastography in patient with nonalcoholic fatty liver disease and compensated and advanced chronic liver disease. Clin Gastroenterol Hepatol. 2020;[e-pub]. Disponible en: https://doi.org/10.1016/j.cgh.2020.06.045

  16. Merriman RB, Ferrell LD, Patti MG, Weston SR. Correlation of paired liver biopsies in morbidly obese patients with suspected no-alcoholic fatty liver disease. Hepatology. 2006;44:874-80.

  17. Velbes Marquetti PE. Propóleos Rojo Oral Cubano en la Esteatohepatitis no alcohólica. 2020. Editorial Nuevo Milenio: La Habana. Cuba.




2020     |     www.medigraphic.com